RecruitingPhase 3Drug trialLow Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular RiskThe Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.